LivingGLP1
Study S000300

Efficacy and Safety of Semaglutide Injection (QLG2065) vs. Ozempic® as add-on to Metformin in Type 2 Diabetics.

ClinicalTrials.gov record

Registration

Registration
NCT05950516
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
NONE
Status
UNKNOWN
Enrollment
478
Start
2023-07-10
Primary completion
2024-11-24
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Conditions
Type 2 Diabetes
Interventions
DRUG:Semaglutide; DRUG:Semaglutide Pen Injector [Ozempic]
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in HbA1c [Week 33]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.